Eun-Ok Im, PhD, MPH, RN, CNS, FAAN, was recently named as the recipient of the 2023 Oncology Nursing Society (ONS) Distinguished Nurse Researcher Award. At this past ONS Congress, Dr. Im gave a presentation on her pioneering use of technology and Internet-based approaches to address racial and ethnic survivorship disparities in the cancer survivorship experience, which she has been among the first to research over the course of her career. In this interview, she provides the background behind this approach and how it has been used to improve survivorship experience for racial/ethnic minority cancer patients. 

The FDA has granted approval to abemaciclib (Verzenio®, Eli Lilly and Company) with endocrine therapy—tamoxifen or an aromatase inhibitor—for treatment of adult patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative, node-positive early breast cancer that is at a high risk of recurrence. Patients cons...

The FDA has granted approval to sacituzumab govitecan-hziy (Trodelvy®, Gilead Sciences, Inc.) for treatment of unresectable, locally advanced, or metastatic hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer. Patients are required to have received at least one prior line of endocrine therapy and t...

The FDA has approved elacestrant (Orserdu™, Stemline Therapeutics, Inc.) for postmenopausal women or adult men with estrogen receptor (ER)–positive, human epidermal growth factor receptor 2 (HER2)–negative, estrogen receptor 1 (ESR1)–mutated advanced or metastatic breast cancer with disease progression subsequent to at least one line of endocrine t...

An educational activity provided by i3 Health has delivered significant improvement in knowledge regarding treatment advances and personalized care for patients with metastatic triple-negative breast cancer (TNBC). Breast cancer is the most commonly diagnosed cancer and the second-leading cause of cancer-related death among women in the United Stat...

At the recent San Antonio Breast Cancer Symposium (SABCS), Yara Abdou, MD, Assistant Professor of Hematology and Oncology and Medical Oncologist at The University of North Carolina School of Medicine, presented her team's research on the disparities that Black women with breast cancer experience. Afterwards, she spoke with Oncology Data Advisor to ...

An educational enduring online activity provided by i3 Health has provided knowledge gains pertaining to enhancing treatment tolerability, adherence, and patient-centered care for metastatic breast cancer. In the United States, breast cancer accounts for approximately 30% of cancer diagnoses among women and is the second-leading cause of cancer dea...

The FDA has approved fam-trastuzumab deruxtecan-nxki (Enhertu®, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)–low breast cancer. This treatment is indicated for patients who have previously undergone chemotherapy in the metastatic setting or who developed disease recurrence ...

The FDA has approved fam-trastuzumab deruxtecan-nxki (Enhertu®, Daiichi Sankyo, Inc.) for treatment of patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)–positive breast cancer. The approval is specific to individuals who have had prior treatment with an anti–HER2-based regimen in the metastatic, neoadjuvant, o...